Literature DB >> 1376909

Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle.

E Shapiro1, V Hartanto, H Lepor.   

Abstract

Anti-desmin and anti-actin are commercially available antibodies that bind to smooth muscle. The present study was designed to compare the staining properties of anti-desmin and anti-actin in the human prostate in order to determine the optimal antibody for quantifying the smooth muscle content of the human prostate. Nineteen male subjects with symptomatic BPH underwent needle biopsy of the prostate. Double-immunoenzymatic staining was performed with peroxidase-anti-peroxidase (PAP) and alkaline phosphatase-anti-alkaline phosphatase (APAAP) techniques. Rabbit anti-desmin:mouse anti-human prostatic acid phosphatase and mouse anti-actin:rabbit anti-human prostatic acid phosphatase were utilized. Computer assisted color image analysis was performed using the Bioquant image analysis system. The percent area density of stroma and epithelium was independent of the antibodies used. The percent area density of smooth muscle in the anti-actin stained tissue sections was twofold greater than the anti-desmin stained tissue sections. A direct relationship was observed for the area density of smooth muscle (r = 0.71; P = 0.0006) and the area density of connective tissue (r = 0.82; P less than 0.001) determined from anti-desmin and anti-actin stained tissue sections. Anti-actin represents the optimal antibody for quantifying the area density of prostate smooth muscle. The reproducibility of the immunoenzymatic staining technique is inferred from the direct relationship observed for area density of epithelium between the different staining techniques.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376909     DOI: 10.1002/pros.2990200402

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Pathophysiology of lower urinary tract symptoms in the aging male population.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

2.  Pathophysiology of benign prostatic hyperplasia in the aging male population.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

Review 3.  Emerging treatment options for benign prostatic obstruction.

Authors:  Brian A Parsons; Hashim Hashim
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

4.  The effects of aging on the molecular and cellular composition of the prostate microenvironment.

Authors:  Daniella Bianchi-Frias; Funda Vakar-Lopez; Ilsa M Coleman; Stephen R Plymate; May J Reed; Peter S Nelson
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

5.  Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo.

Authors:  Yalçin Evliyaoğlu; Refik Burgut
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

6.  Prostate specific antigen and acinar density: a new dimension, the "Prostatocrit".

Authors:  Simon Robinson; Marc Laniado; Bruce Montgomery
Journal:  Int Braz J Urol       Date:  2017 Mar-Apr       Impact factor: 1.541

7.  Defined medium for normal adult human prostatic stromal cells.

Authors:  D M Peehl; R G Sellers; S T Wong
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

8.  High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification.

Authors:  Yi Zhu; Tobias Weiss; Qiushi Zhang; Rui Sun; Bo Wang; Xiao Yi; Zhicheng Wu; Huanhuan Gao; Xue Cai; Guan Ruan; Tiansheng Zhu; Chao Xu; Sai Lou; Xiaoyan Yu; Ludovic Gillet; Peter Blattmann; Karim Saba; Christian D Fankhauser; Michael B Schmid; Dorothea Rutishauser; Jelena Ljubicic; Ailsa Christiansen; Christine Fritz; Niels J Rupp; Cedric Poyet; Elisabeth Rushing; Michael Weller; Patrick Roth; Eugenia Haralambieva; Silvia Hofer; Chen Chen; Wolfram Jochum; Xiaofei Gao; Xiaodong Teng; Lirong Chen; Qing Zhong; Peter J Wild; Ruedi Aebersold; Tiannan Guo
Journal:  Mol Oncol       Date:  2019-09-18       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.